# Junta clínica — PT-pseudo_25007bb807d7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_25007bb807d7",
  "pid": "PT-pseudo_25007bb807d7",
  "task": 1,
  "psa": 17.0,
  "age": 61,
  "months": 1,
  "pirads": "5",
  "psad": 0.462,
  "psav": 1.29,
  "psap": 16.1,
  "vol": 36.82,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.85766834,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "83 kg",
    "height": "193 cm",
    "bmi": "22.3",
    "bp": "122/68 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent prostate-specific antigen elevation prompted mpMRI scheduling."
    },
    {
      "s": "History",
      "t": "A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "office administrator",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "11 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_25007bb807d7
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 17.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.462 ng/mL²
  - PSA velocity: 1.29 ng/mL/yr
  - Prior PSA: 16.1 ng/mL
  - Prostate volume: 36.82 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.85766834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.

Vitals: weight 83 kg, height 193 cm, BMI 22.3, BP 122/68 mmHg, HR 74 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2015).

Chief complaint: Persistent prostate-specific antigen elevation prompted mpMRI scheduling.

History: A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly.

Patient info: office administrator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 11 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.90
  uncertainty  +/- 0.04 epistemic (95% band 0.83-0.97); among patients I cannot tell apart the outcome was 0.46 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 17.0, PSAD 0.462, age 61, DRE Normal -> BIOPSY (clear). He wrote: "P5 in 61 year patient"
  2. distance 1.08: PI-RADS 5, PSA 9.0, PSAD 0.409, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P5 in a man with high PSA"
  3. distance 1.14: PI-RADS 5, PSA 22.0, PSAD 0.696, age 68, DRE Normal -> BIOPSY (clear). He wrote: "Biopsy-naive PIRADS 5 needs biopsy"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, age=important, psad=noted, fh=noted, psa=important, vol=noted, dre=noted, pirads=decisive.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines indicate that a PI-RADS score of 3 or higher is used to trigger a biopsy. "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375]." This requires a decision on whether to proceed based on the imaging finding.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's high probability of biopsy is not decisive because the guideline focuses on the PI-RADS score, which is present, but the guideline does not provide a definitive threshold for action based on that score alone without considering other factors. The cohort criterion suggests that the decision is highly dependent on the PI-RADS score, which is the primary factor in this situation.

WHAT WE STILL NEED
The panel already contains the PI-RADS score of 5, which is $\ge 3$, which is the trigger according to the guideline.
The panel already contains the prior-biopsy status as "None," which is a factor mentioned in the guideline regarding biopsy-naïve patients.
The panel already contains the csPCa predicted probability of 0.85766834, which is a factor that influences the decision in the context of the guideline.
The panel already contains the PSA density of 0.462 ng/mL², which is a factor mentioned in the guideline regarding risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly points towards biopsy based on the PI-RADS score and the cohort criterion, but we must establish the context from the opened documents.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, and is it compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend beyond the headline number?
  previous_notes (get_previous_notes) -> What was the prior biopsy result (Gleason/ISUP), surveillance protocol status, number/dates of biopsy sessions, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the Gleason or ISUP grade from the previous notes?
  Q2. Is there a surveillance protocol with a confirmatory biopsy due?
  Q3. What is the PSA trend beyond the headline value?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is "18 mm hypointense focus within the right peripheral zone, spanning the base to mid-gland". It is compared against an earlier study: "new".
psa_trend
The serial PSA value trend beyond the headline number is: [{"date": "Jun 2022", "val": 5.7}, {"date": "Jan 2023", "val": 11.3}, {"date": "Sep 2023", "val": 15.4}, {"date": "May 2024", "val": 3.1}, {"date": "Jan 2025", "val": 17.0}].
previous_notes
The prior biopsy result (Gleason/ISUP), surveillance protocol status, number/dates of biopsy sessions, and planned treatment is: "Prior biopsy: None", "Surveillance: not recorded", "Biopsy sessions: None", "Treatment: none recorded".

WHAT I DID NOT OPEN
I did not open the family-history anamnesis because the previous notes did not contain specific details on this topic.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the right peripheral zone.
csPCa predicted probability 0.85766834.

Findings that argue AGAINST sampling this patient now:
Prior biopsy status is "None".

WHERE THIS LEANS
The imaging findings and the cohort criterion strongly point towards biopsy, which aligns with the Expert-Structured and Expert-Cohort bids.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 17.00 ng/mL over 5 points spanning 31 months; velocity +2.18 ng/mL per year; doubling time about 63 months.
PROJECTION at 6 months: 52.6 ng/mL, conformal 95% band 15.1-183.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.81
  uncertainty  +/- 0.07 epistemic (95% band 0.68-0.94), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.90  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.81  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: bx=noted, age=important, psad=noted, fh=noted, psa=important, vol=noted, dre=noted, pirads=decisive.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—directly address all three moderator questions.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of BIOPSY, as the PI-RADS 5 finding in the radiology report and the prior biopsy status of "None" in the previous notes align with the cohort criterion and the precedent-based decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the Gleason or ISUP grade from the previous notes? Answered by previous_notes: "Prior biopsy: None".
Q2. Is there a surveillance protocol with a confirmatory biopsy due? Answered by previous_notes: "Surveillance: not recorded".
Q3. What is the PSA trend beyond the headline value? Answered by psa_trend: A rising trend with a last value of 17.0 ng/mL and a velocity of +2.18 ng/mL per year.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score from the radiology report is the most decisive variable, as it directly triggers the EAU guideline threshold. The prior biopsy status ("None") is also critical as it informs the risk stratification. The PSA trend indicates disease activity.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the strong alignment between the imaging findings (PI-RADS 5) and the established cohort criterion, which is confirmed by the panel protocol.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the high PI-RADS 5 score, which meets the imaging threshold for action, and the patient's prior biopsy status being 'None'. This decision is strongly supported by the cohort criterion and confirmed by the precedent-based panel protocol. The rising PSA trend further indicates disease activity, leading to a clear convergence toward proceeding with a biopsy.

What carried weight: bx=noted, age=important, psad=noted, psa=important, vol=noted, pirads=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes
